What this means
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 50–64
- Where
- 2 sites
The science
- Registered title
- Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years
- Trial ID
- NCT07428759 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Pneumonia, Bacterial
- What is tested
- Pn-MAPS30plus, PCV20
- Sponsor
- GlaxoSmithKline
- Ages
- 50 Years to 64 Years
- Dates
- First posted Feb 24, 2026 · updated Oct 27, 2026
Registry summary
This study will evaluate the safety and immune response of a new formulation of pneumococcal vaccine, PnMAPS30plus, in healthy adults aged 50 to 64 years. Participants will receive a single dose of either the investigational vaccine or an approved pneumococcal vaccine (PCV20) and will be monitored for approximately six months. The study aims to determine if PnMAPS30plus is safe and well-tolerated and whether it helps the body produce antibodies that protect against pneumococcal disease.
Sites (2)
- GSK Investigational Site, Norwood, South Australia, Australia
- GSK Investigational Site, Camberwell, Victoria, Australia